Drug-resistant herpes simplex virus in HIV infected patients

Acta Dermatovenerologica Croatica

Volumn 16, Issue 4, 2008, Pages 204-208

  Lolis, Margarita S ^a   González, Lenis ^a   Cohen, Philip J ^a   Schwartz, Robert A ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Herpes simplex virus type 2; HIV infection; HSV2 drug resistance; HSV2 therapy

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DISTAMYCIN A; FAMCICLOVIR; FOSCARNET; HELICASE PRIMASE INHIBITOR; IMIQUIMOD; IMMUNOMODULATING AGENT; RESIQUIMOD; SCV 07; UNCLASSIFIED DRUG; VALACICLOVIR;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONCURRENT INFECTION; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; VAGINA FLORA; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HERPES SIMPLEX; HIV INFECTIONS; HUMANS; SIMPLEXVIRUS;

EID: 58849146583     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol 2007;57:737-63.
2. Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus 2 and HIV co-infection. Drugs 2007;67:155-74.
3. Corey L. Synergistic copathogens-HIV-1 and HSV-2. N Engl J Med 2007;356: 854-6.
4. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections. Arch Intern Med 2008;168:1137-44.
5. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1 infected persons. Clin Infect Dis 2006;43:347-56.
6. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwes S, et al. Effect of acyclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomized, double blind, placebo-controlled trial. Lancet 2008;371:2109-19.
7. Sheth PM, Sunderji S, Shin LYY, Rebbapragada A, Huiber S, Kimani J, et al. Coinfection with herpes simplex virus type 2 is associated with specific T cell responses and immune activation. J Infect Dis 2008;197:1394-401.
8. Van de Perre P, Segondy M, Foulogne V, Ouedraogo A, Konate I, Huraux JM, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008;8:490-7.
9. Wald A, Corey L. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? J Infect Dis 2007;195:1509-12.
10. Corey L. Herpes simplex virus type 2 and HIV-1: the dialogue between the 2 organisms continues. J Infect Dis 2007;195:1242-4.
11. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, et al. Reduction of HIV-RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356:790-9.
12. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, et al. Impact of suppressive herpes therapy on genital HIV-RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006;20:2305-13.
13. Zuckerman R, Lucchetti A, Whittington W, Sanchez J, Coombs RW, Zuniga R, et al. HSV suppression with valacyclovir reduces rectal and blood plasma HIV levels in HIV, HSV2 seropositive men: a randomized, double blind placebo controlled crossover trial. J Infect Dis 2007;196:1500-8.
14. Cooper DA, Pehrson PO, Pedersen C, Moroni M, Oksenhendler E, Rozenbaum W, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. AIDS 1993;7:197-207.
15. Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs; 3-year follow-up. J Clin Microbiol 2004;42:242-9.
16. Ziyaeyan M, Alborzi A, Japoni A, Kadivar M, Davarpanah MA, Pourabbas B, et al. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome. Int J Dermatol 2007;46:1263-6.
17. Weinberg A, Leary JJ, Sarisky RT, Levin MJ. Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues. J Clin Virol 2007;38:139-45.
18. Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004;39:S248-57.
19. Biswas S, Field HJ. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations. Antivir Chem Chemother 2008;19:1-6.
20. Saint-Leger E, Fillet AM, Malvy D, Rabanel B, Caumes E. Efficacy of cidofovir in an HIV infected patient with an acyclovir and foscarnet resistant herpes simplex virus. Ann Dermatol Venereol 2001;128:747-9.
21. Martinez V, Molina JM, Scieux C, Ribaud P, Morfin F. Topical imiquimod for recurrent acyclovir-resistant HSV infection. Am J Med 2005;119:e9-11.
22. Miller RL, Meng TC, Tomai MA. The antiviral activity of toll-like receptor 7 and 7/8 agonists. Drug New Prospect 2008;21:61-87.
23. Gilbert J, Drehs MM, Weinberg JM. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol 2001;137:1015-7.
24. Biswas S, Tiley LS, Zimmermann H, Birkmann A, Field HJ. Mutations close to functional motif IV in HSV01 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect viral growth rate and pathogencitiy. Antiviral Res 2008. 2008;80:81-5.
25. Matteoli B, Bernardini S, Iuliano R, Parenti S, Freer G, Broccolo F, et al. In vitro antiviral activity of distamycin A against clinical isolates of herpes simplex virus 1 and 2 from transplanted patients. Intervirology 2008;51:166-72.
26. Rose WA, Tuthill C, Pyles RB. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents 2008. 2008;32:262-6.